Myelodysplastic Syndrome - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Myelodysplastic Syndromes > What Your Doctor is Reading About Myelodysplastic Syndromes > Clinical Trials

Clinical Trials

1. The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.

Author: Cho BS; Kim YJ; Cho SG; Kim SY; Eom KS; Kim HJ; Lee S; Min CK; Kim DW; Lee JW; Min WS; Kim CC;
Institution: Catholic Hematopoietic Stem Cell Transplantation Center, The Catholic University of Korea, Seoul, Korea.
Journal: Int J Hematol. 2007 Jun;85(5):446-55.
Abstract URL: Click here to view abstract

2. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

Author: Soriano AO; Yang H; Faderl S; Estrov Z; Giles F; Ravandi F; Cortes J; Wierda WG; Ouzounian S; Quezada A; Pierce S; Estey EH; Issa JP; Kantarjian HM; Garcia-Manero G;
Institution: Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Blood. 2007 Oct 1;110(7):2302-8. Epub 2007 Jun 27.
Abstract URL: Click here to view abstract

3. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.

Author: Heidel F; Cortes J; Rucker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Dohner H; Kantarjian H; Fischer T; Heidel F; Cortes J; Rucker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Dohner H; Kantarjian H; Fischer T;
Institution: Department Internal Medicine III, University-Hospital, Mainz, Germany.
Journal: Cancer. 2007 Mar 1;109(5):907-14.
Abstract URL: Click here to view abstract

4. The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study.

Author: Ito Y; Ohyashiki K; Yoshida I; Takeuchi M; Aoyama Y; Mugitani A; Matsuura Y; Wakita H; Matsuda M; Sakamoto E; Kiguchi T; Urabe A; Tamura K; Kanamaru A; Masaoka T; Ito Y; Ohyashiki K; Yoshida I; Takeuchi M; Aoyama Y; Mugitani A; Matsuura Y; Wakita H; Matsuda M; Sakamoto E; Kiguchi T; Urabe A; Tamura K; Kanamaru A; Masaoka T;
Institution: First Department of Internal Medicine (Hematology Division), Tokyo Medical University, Tokyo, Japan. yito@tokyo-med.ac.jp
Journal: Int J Hematol. 2007 Feb;85(2):121-7.
Abstract URL: Click here to view abstract

5. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.

Author: Oran B; Giralt S; Saliba R; Hosing C; Popat U; Khouri I; Couriel D; Qazilbash M; Anderlini P; Kebriaei P; Ghosh S; Carrasco-Yalan A; de Meis E; Anagnostopoulos A; Donato M; Champlin RE; de Lima M; Oran B; Giralt S; Saliba R; Hosing C; Popat U; Khouri I; Couriel D; Qazilbash M; Anderlini P; Kebriaei P; Ghosh S; Carrasco-Yalan A; de Meis E; Anagnostopoulos A; Donato M; Champlin RE; de Lima M;
Institution: M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Journal: Biol Blood Marrow Transplant. 2007 Apr;13(4):454-62. Epub 2007 Feb 8.
Abstract URL: Click here to view abstract

6. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

Author: Valcarcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Pinana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simon JA; Sierra J; Valcarcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Pinana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simon JA; Sierra J;
Institution: Hospital de la Santa Creu i Sant Pau, Universitat Autonoma Barcelona, Barcelona, Spain. dvalcarcel@santpau.es
Journal: J Clin Oncol. 2008 Feb 1;26(4):577-84. Epub 2007 Dec 17.
Abstract URL: Click here to view abstract

7. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.

Author: Frankel A; Liu JS; Rizzieri D; Hogge D; Frankel A; Liu JS; Rizzieri D; Hogge D;
Institution: Scott & White Cancer Research Institute, Temple, TX, USA.
Journal: Leuk Lymphoma. 2008 Mar;49(3):543-53.
Abstract URL: Click here to view abstract

8. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes.

Author: Siitonen T; Timonen T; Juvonen E; Terava V; Kutila A; Honkanen T; Mikkola M; Hallman H; Kauppila M; Nylanden P; Poikonen E; Rauhala A; Sinisalo M; Suominen M; Savolainen ER; Koistinen P;
Institution: Department of Internal Medicine, Oulu University Hospital, OYS, Finland. timo.siitonen@ppshp.fi
Journal: Haematologica. 2007 Aug;92(8):1119-22.
Abstract URL: Click here to view abstract

9. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Author: Malcovati L; Germing U; Kuendgen A; Della Porta MG; Pascutto C; Invernizzi R; Giagounidis A; Hildebrandt B; Bernasconi P; Knipp S; Strupp C; Lazzarino M; Aul C; Cazzola M;
Institution: Department of Hematology, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy.
Journal: J Clin Oncol. 2007 Aug 10;25(23):3503-10.
Abstract URL: Click here to view abstract

10. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Author: Raza A; Reeves JA; Feldman EJ; Dewald GW; Bennett JM; Deeg HJ; Dreisbach L; Schiffer CA; Stone RM; Greenberg PL; Curtin PT; Klimek VM; Shammo JM; Thomas D; Knight RD; Schmidt M; Wride K; Zeldis JB; List AF;
Institution: Rush University Medical Center, Chicago, IL, USA.
Journal: Blood. 2008 Jan 1;111(1):86-93. Epub 2007 Sep 24.
Abstract URL: Click here to view abstract

11. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Author: Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R 3rd; Shen L; Nimer SD; Leavitt R; Raza A; Saba H;
Institution: Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org
Journal: Cancer. 2006 Apr 15;106(8):1794-803.
Abstract URL: Click here to view abstract

12. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients.

Author: Ruter B; Wijermans PW; Lubbert M;
Institution: Division of Hematology/Oncology, Department of Internal Medicine I, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
Journal: Cancer. 2006 Apr 15;106(8):1744-50.
Abstract URL: Click here to view abstract

13. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.

Author: Martino R; Iacobelli S; Brand R; Jansen T; van Biezen A; Finke J; Bacigalupo A; Beelen D; Reiffers J; Devergie A; Alessandrino E; Mufti GJ; Barge R; Sierra J; Ruutu T; Boogaerts M; Falda M; Jouet JP; Niederwieser D; de Witte T;
Institution: Division of Clinical Hematology, Hopital de la Sant Creu i Sant Pau, Autonomous University of Barcelona, Spain. rmartino@santpau.es
Journal: Blood. 2006 Aug 1;108(3):836-46. Epub 2006 Apr 4.
Abstract URL: Click here to view abstract

14. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.

Author: Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P; Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P;
Institution: Institut Paoli-Calmettes, Marseille, France. veyn@marseille.fnclcc.fr
Journal: J Clin Oncol. 2006 Jun 1;24(16):2465-71. Epub 2006 May 1.
Abstract URL: Click here to view abstract

15. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.

Author: Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF; Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF;
Institution: UCLA Division of Hematology-Oncology, University of California Los Angeles, San Diego, CA 90095, USA. garyjs@ucla.edu
Journal: J Clin Oncol. 2006 Jun 1;24(16):2456-64. Epub 2006 May 1.
Abstract URL: Click here to view abstract

16. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.

Author: Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P; Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P;
Institution: Department of Haematology, Nice University Hospital, Nice, France.
Journal: Br J Haematol. 2006 Jun;133(5):513-9.
Abstract URL: Click here to view abstract

17. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.

Author: Musto P; Falcone A; Sanpaolo G; Bodenizza C; Musto P; Falcone A; Sanpaolo G; Bodenizza C;
Institution: Hematology and Stem Cell Transplantation Unit, IRCCS "Casa Sollievo della Sofferenza" Hospital, I-71013, S. Giovanni Rotondo, Italy. p.musto@tin.it
Journal: Leuk Res. 2006 Apr;30(4):385-8. Epub 2005 Oct 10.
Abstract URL: Click here to view abstract

18. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.

Author: Shimoni A; Hardan I; Shem-Tov N; Yeshurun M; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A; Shimoni A; Hardan I; Shem-Tov N; Yeshurun M; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A;
Institution: The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel. ashimoni@sheba.health.gov.il
Journal: Leukemia. 2006 Feb;20(2):322-8.
Abstract URL: Click here to view abstract

19. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes.

Author: Raza A; Lisak L; Billmeier J; Pervaiz H; Mumtaz M; Gohar S; Wahid K; Galili N;
Institution: The Radhey Khanna Center for MDS Research, University of Massachusetts Medical Center, Worcester, MA 01605, USA. azra.raza@umass.edu
Journal: Leuk Lymphoma. 2006 Mar;47(3):433-40.
Abstract URL: Click here to view abstract

20. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.

Author: Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R; Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R;
Institution: Department of Hematology and Oncology, University of Genoa, Azienda Ospedaliera Universitaria San Martino di Genova, Genoa, Italy.
Journal: Ann Hematol. 2006 Mar;85(3):174-80. Epub 2006 Jan 12.
Abstract URL: Click here to view abstract

21. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).

Author: Kroger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A;
Institution: Department of Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany. nkroeger@uke.uni-hamburg.de
Journal: Bone Marrow Transplant. 2006 Feb;37(4):339-44.
Abstract URL: Click here to view abstract

22. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Author: Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D; Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D;
Institution: University of Cologne, Cologne, Germany. oliver.cornely@uni-koeln.de
Journal: N Engl J Med. 2007 Jan 25;356(4):348-59.
Abstract URL: Click here to view abstract

23. Treatment of myelodysplastic syndrome with cyclosporin A.

Author: Chen S; Jiang B; Da W; Gong M; Guan M;
Institution: Department of Oncology, Peking Union Medical College (PUMC), Hospital No.1, Beijing, China. chen.sc@medmail.com.cn
Journal: Int J Hematol. 2007 Jan;85(1):11-7.
Abstract URL: Click here to view abstract

24. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.

Author: Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB; Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB;
Institution: Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. smallt@mskcc.org
Journal: Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44.
Abstract URL: Click here to view abstract

25. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.

Author: Moreno-Aspitia A; Colon-Otero G; Hoering A; Tefferi A; Niedringhaus RD; Vukov A; Li CY; Menke DM; Geyer SM; Alberts SR;
Institution: Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
Journal: Cancer. 2006 Aug 15;107(4):767-72.
Abstract URL: Click here to view abstract

26. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.

Author: Lim ZY; Ho AY; Ingram W; Kenyon M; Pearce L; Czepulkowski B; Devereux S; Duarte RF; Pagliuca A; Mufti GJ; Lim ZY; Ho AY; Ingram W; Kenyon M; Pearce L; Czepulkowski B; Devereux S; Duarte RF; Pagliuca A; Mufti GJ;
Institution: Department of Haematological Medicine, Kings College London and Kings College Hospital, UK.
Journal: Br J Haematol. 2006 Oct;135(2):201-9. Epub 2006 Aug 25.
Abstract URL: Click here to view abstract

27. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Author: List A; Dewald G; Bennett J; Giagounidis A; Raza A; Feldman E; Powell B; Greenberg P; Thomas D; Stone R; Reeder C; Wride K; Patin J; Schmidt M; Zeldis J; Knight R;
Institution: University of South Florida College of Medicine and Malignant Hematology Division, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612-9497, USA. heberten@moffitt.usf.edu
Journal: N Engl J Med. 2006 Oct 5;355(14):1456-65.
Abstract URL: Click here to view abstract

28. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.

Author: Giraldo P; Nomdedeu B; Loscertales J; Requena C; de Paz R; Tormo M; Navarro P; Benedit P; Gasquet JA;
Institution: Haematology Services, University of Miguel Servet Hospital, Zaragoza, Spain. pgiraldo@salud.aragon.es
Journal: Cancer. 2006 Dec 15;107(12):2807-16.
Abstract URL: Click here to view abstract

29. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.

Author: Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP;
Institution: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org
Journal: Cancer. 2007 Jan 15;109(2):265-73.
Abstract URL: Click here to view abstract